Nigel Lange
Follow
Get notifications in MyBN when activity occurs.
Nigel Lange
Chief Executive, Managing Director / OncoSil Medical
Nigel Lange has over 30 years of experience in the medical devices industry.
He joined OncoSil in May 2020 as EMEA president and became chief executive in January 2021.
Mr Lange had held various leadership roles during his 15-year tenure with Sirtex Medical, a company involved in brachytherapy treatment for liver cancer. He was chief executive of Sirtex's European business, responsible for establishing their brachytherapy device in over 300 centres across Europe and Middle East; group chief commercial officer where he was responsible for all commercial aspects of the global business; as well as interim roles including interim group chief executive and interim chief executive of Asia Pacific.
He joined OncoSil in May 2020 as EMEA president and became chief executive in January 2021.
Mr Lange had held various leadership roles during his 15-year tenure with Sirtex Medical, a company involved in brachytherapy treatment for liver cancer. He was chief executive of Sirtex's European business, responsible for establishing their brachytherapy device in over 300 centres across Europe and Middle East; group chief commercial officer where he was responsible for all commercial aspects of the global business; as well as interim roles including interim group chief executive and interim chief executive of Asia Pacific.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 1723rd | Blue Star Helium | -68% | 9% |
| 1765th | OncoSil Medical | -72% | -44% |
| 1796th | Firebrick Pharma | -74% | |
| 1822nd | Horseshoe Metals | -77% | -5% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 970th |  | OncoSil Medical | $1.5m |
| 1165th | | Firebrick Pharma | $23k |
| 1166th | | Horseshoe Metals | $21k |
| 1172nd | | Blue Star Helium | $12k |
| 1173rd | | Real Energy Corporation | $11k |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Chief Executive, Managing Director, OncoSil Medical | 14 Apr 2021 |
